Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Macular Edema - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H2 2015', provides an overview of the Diabetic Macular Edema's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Macular Edema Overview 8 Therapeutics Development 9 Pipeline Products for Diabetic Macular Edema - Overview 9 Pipeline Products for Diabetic Macular Edema - Comparative Analysis 10 Diabetic Macular Edema - Therapeutics under Development by Companies 11 Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 13 Diabetic Macular Edema - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Diabetic Macular Edema - Products under Development by Companies 18 Diabetic Macular Edema - Products under Investigation by Universities/Institutes 21 Diabetic Macular Edema - Companies Involved in Therapeutics Development 22 Aciont Inc. 22 ActiveSite Pharmaceuticals, Inc. 23 Acucela Inc. 24 Aerpio Therapeutics, Inc. 25 Allergan Plc 26 Ampio Pharmaceuticals, Inc. 27 Astellas Pharma Inc. 28 Avalanche Biotechnologies, Inc. 29 Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 30 Chong Kun Dang Pharmaceutical Corp. 31 Dyax Corp. 32 EyeGate Pharmaceuticals, Inc. 33 EyeGene, Inc. 34 F. Hoffmann-La Roche Ltd. 35 Gene Signal International SA 36 Genmab A/S 37 Icon Bioscience, Inc. 38 Kala Pharmaceuticals, Inc. 39 Kowa Company, Ltd. 40 Mabion SA 41 MacuCLEAR, Inc. 42 NicOx S.A. 43 Oculis ehf 44 Ohr Pharmaceutical Inc. 45 Pfizer Inc. 46 Quark Pharmaceuticals, Inc. 47 R-Tech Ueno, Ltd. 48 Regeneron Pharmaceuticals, Inc. 49 Santen Pharmaceutical Co., Ltd. 50 SciFluor Life Sciences, LLC 51 Senju Pharmaceutical Co., Ltd. 52 ThromboGenics NV 53 Verseon Corporation 54 Diabetic Macular Edema - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 60 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 (aflibercept + nesvacumab) - Drug Profile 66 abicipar pegol - Drug Profile 67 aganirsen - Drug Profile 70 AKB-9778 - Drug Profile 72 ALG-1001 - Drug Profile 74 Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 76 ASP-440 - Drug Profile 77 ASP-8232 - Drug Profile 79 AVA-101 - Drug Profile 80 conbercept - Drug Profile 82 danazol - Drug Profile 84 dexamethasone acetate - Drug Profile 85 dexamethasone acetate - Drug Profile 87 dexamethasone dipropionate - Drug Profile 89 difluprednate - Drug Profile 90 Drug for Diabetic Macular Edema - Drug Profile 91 Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema - Drug Profile 92 Drugs to Inhibit Tyrosine Kinase for Ophthalmology - Drug Profile 93 EG-Mirotin - Drug Profile 94 emixustat hydrochloride - Drug Profile 96 KVD-001 - Drug Profile 98 lanadelumab - Drug Profile 99 LKA-651 - Drug Profile 100 loteprednol etabonate - Drug Profile 101 MC-4001 - Drug Profile 102 methotrexate - Drug Profile 103 MTP-131 - Drug Profile 104 NCX-422 - Drug Profile 106 NCX-434 - Drug Profile 107 nesvacumab - Drug Profile 108 NM-108 - Drug Profile 110 ocriplasmin (recombinant) - Drug Profile 111 OLX-303 - Drug Profile 114 PF-04634817 - Drug Profile 115 PF-655 - Drug Profile 116 ranibizumab - Drug Profile 118 ranibizumab biosimilar - Drug Profile 121 ranibizumab biosimilar - Drug Profile 122 RC-1 Alpha - Drug Profile 123 ripasudil - Drug Profile 124 RTU-1096 - Drug Profile 125 RX-10045 - Drug Profile 126 SF-0166 - Drug Profile 128 Small Molecule for Diabetic Macular Edema - Drug Profile 129 Small Molecule to Inhibit Kallikrein for DME - Drug Profile 130 Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 131 Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile 133 squalamine lactate - Drug Profile 134 teprotumumab - Drug Profile 137 TG-758 - Drug Profile 139 TG-931 - Drug Profile 140 triamcinolone acetonide - Drug Profile 141 Diabetic Macular Edema - Recent Pipeline Updates 142 Diabetic Macular Edema - Dormant Projects 182 Diabetic Macular Edema - Discontinued Products 185 Diabetic Macular Edema - Product Development Milestones 186 Featured News & Press Releases 186 Appendix 194 Methodology 194 Coverage 194 Secondary Research 194 Primary Research 194 Expert Panel Validation 194 Contact Us 194 Disclaimer 195
List of Tables
Number of Products under Development for Diabetic Macular Edema, H2 2015 13 Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 15 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Comparative Analysis by Unknown Stage Development, H2 2015 21 Products under Development by Companies, H2 2015 22 Products under Development by Companies, H2 2015 (Contd..1) 23 Products under Development by Companies, H2 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2015 25 Diabetic Macular Edema - Pipeline by Aciont Inc., H2 2015 26 Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2015 27 Diabetic Macular Edema - Pipeline by Acucela Inc., H2 2015 28 Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2015 29 Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2015 30 Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 31 Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2015 32 Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H2 2015 33 Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H2 2015 34 Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 35 Diabetic Macular Edema - Pipeline by Dyax Corp., H2 2015 36 Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 37 Diabetic Macular Edema - Pipeline by EyeGene, Inc., H2 2015 38 Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 39 Diabetic Macular Edema - Pipeline by Gene Signal International SA, H2 2015 40 Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2015 41 Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2015 42 Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2015 43 Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2015 44 Diabetic Macular Edema - Pipeline by Mabion SA, H2 2015 45 Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H2 2015 46 Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2015 47 Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2015 48 Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2015 49 Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2015 50 Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 51 Diabetic Macular Edema - Pipeline by R-Tech Ueno, Ltd., H2 2015 52 Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 53 Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015 54 Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H2 2015 55 Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2015 56 Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2015 57 Diabetic Macular Edema - Pipeline by Verseon Corporation, H2 2015 58 Assessment by Monotherapy Products, H2 2015 59 Assessment by Combination Products, H2 2015 60 Number of Products by Stage and Target, H2 2015 62 Number of Products by Stage and Mechanism of Action, H2 2015 65 Number of Products by Stage and Route of Administration, H2 2015 67 Number of Products by Stage and Molecule Type, H2 2015 69 Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H2 2015 146 Diabetic Macular Edema - Dormant Projects, H2 2015 186 Diabetic Macular Edema - Dormant Projects (Contd..1), H2 2015 187 Diabetic Macular Edema - Dormant Projects (Contd..2), H2 2015 188 Diabetic Macular Edema - Discontinued Products, H2 2015 189
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
